Search

Alkermes PLC

Slēgts

SektorsVeselības aprūpe

48.84 1.1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

47.47

Max

49

Galvenie mērījumi

By Trading Economics

Ienākumi

67M

501K

Pārdošana

103M

496M

P/E

Sektora vidējais

131.184

57.371

EPS

0.52

Peļņas marža

0.101

Darbinieki

2,050

EBITDA

76M

54M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+20.53% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 27. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-426M

8.4B

Iepriekšējā atvēršanas cena

47.74

Iepriekšējā slēgšanas cena

48.84

Ziņu noskaņojums

By Acuity

10%

90%

8 / 340 Rangs Healthcare

Alkermes PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. aug. 19:51 UTC

Alkermes Plc's shares are higher, supported by strong biotechnology sector momentum, though the stock is pulling back from earlier session highs.

2026. g. 20. aug. 20:01 UTC

Alkermes Plc shares are lower, impacted by broader weakness in the Biotechnology sector. The stock is trading below its 20-day moving average.

2026. g. 19. aug. 19:26 UTC

Alkermes Plc is trading higher, maintaining momentum since Tuesday's close, despite no specific news driving the price movement.

2026. g. 18. aug. 19:16 UTC

News

Alkermes Plc shares are lower after an insider sold 7,576 shares at prices between $49.19 and $49.65, raising investor concerns about the outlook.

2026. g. 17. aug. 23:31 UTC

Alkermes Plc shares are higher in after-market trading, reflecting a cumulative gain since Monday's close amid broader market volatility and fluctuating crude oil prices.

2026. g. 14. aug. 19:46 UTC

Alkermes Plc shares are lower today amid broader market weakness following a reported decline in U.S. retail sales for July.

2026. g. 13. aug. 19:26 UTC

Alkermes Plc shares are lower during Thursday's session, breaking a trend of higher closes. Broader market sentiment may be influenced by rising jobless claims.

2026. g. 12. aug. 21:51 UTC

Alkermes shares are higher in after-market trading, reflecting positive momentum amid easing inflation concerns and a broader market recovery.

2026. g. 11. aug. 19:26 UTC

Alkermes Plc shares are trading lower today, remaining near the lower end of their one-month range amid a lack of specific company news.

2026. g. 10. aug. 19:46 UTC

Alkermes shares are advancing today, despite earlier fluctuations and no specific news. Broader market uncertainty follows a decline in U.S. employment reported last Friday.

2026. g. 6. aug. 19:36 UTC

Alkermes Plc shares are lower today, reflecting unusual volatility and trading significantly below the 20-day moving average. No specific news was identified.

2026. g. 5. aug. 19:56 UTC

Alkermes Plc shares are lower Wednesday, continuing a decline since Tuesday's close, despite broader market optimism from falling oil prices and potential diplomatic resolutions.

2026. g. 4. aug. 19:26 UTC

News

Alkermes Plc shares are lower today amid concerns over recent insider sales by executives, despite the company's gross margin of 80.22%.

2026. g. 3. aug. 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

2026. g. 31. jūl. 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

2026. g. 30. jūl. 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

2026. g. 29. jūl. 20:03 UTC

News
Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

2026. g. 28. jūl. 20:02 UTC

News
Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

2026. g. 24. jūl. 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

2026. g. 22. jūl. 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

2026. g. 21. jūl. 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

2026. g. 20. jūl. 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Alkermes PLC Prognoze

Cenas mērķis

By TipRanks

20.53% augšup

Prognoze 12 mēnešiem

Vidējais 58.25 USD  20.53%

Augstākais 65 USD

Zemākais 38 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Alkermes PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

12 ratings

9

Pirkt

2

Turēt

1

Pārdot

Noskaņojums

By Acuity

8 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat